Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis

Table 1 Baseline features of 14 studies

Author	Year	Region	Sample size	Age (median/range)	Gender (male/ female)	Stage	Indexes	Cut-off values	Study design	Outcome	Time point	NOS score
Mazzaschi [23]	2020	Italy	109	72 (41–85)	73/36	IIIB–IV	sPD-L1	113 pg/ml	P	PFS/OS	Pre	8
Wang [24]	2022	China	149	-	119/30	II–IV	exoPD-L1	0.54 pg/ml	P	PFS	Pre	8
Guibert [25]	2018	France	96	-	-	IV	PD-L1 in CTCs	1%/ 5%/10%	P	PFS/OS	Pre	7
Yang [26]	2021	China	21	60	-	Advanced	sPD-L1/exoPD-L1	-	P	PFS/OS	Post	7
Dall'Olio [27]	2021	Italy	39	68	24/15	Advanced	PD-L1 in CTCs	1	P	PFS/OS	Post	8
Tiako Meyo [28]	2020	France	87	66 (60–69)	29/22	IV	sPD-L1	0.156 ng/ml	P	PFS/OS	Pre/Post	8
Costantini [31]	2018	France	43	-	29/14	I–IV	sPD-L1	33.97 pg/ml	P	PFS/OS	Pre/Post	7
Okuma [32]	2018	Japan	39	75	29/10	IV/ recurrent	sPD-L1	3.357 ng/ml	p	OS	Pre	6
Murakami [33]	2020	Japan	233	63 (30–84)	152/81	Advanced	sPD-L1	90 pg/ml	R	PFS/OS	Pre	7
Zizzari [34]	2020	Italy	22	65	16/6	IV	sPD-L1	-	P	OS	Pre	7
Dhar [35]	2018	America	22	67	13/9	IV	PD-L1 in CTCs	2	P	PFS	Pre	7
Zhang [36]	2020	China	16	-	-	III–IV	PD-L1 in CTCs	-	P	PFS	Post	6
Ikeda [37]	2021	Japan	44	68 (49–86)	33/11	III–IV	PD-L1 in CTCs	7.7%	P	PFS/OS	Post	7
Zhang [38]	2022	China	30	56 (48–69)	22/8	III–IV	PD-L1 in CTCs	32.5%	P	PFS/OS	Pre	7

Aberrations: P Prospective studies,R Retrospective studies, Pre Pre-treatment, Post Post-treatment (Dynamic changes); OS Overall survival, PFS Progression-free survival

ISSN: 1477-7819